Segluromet (ertugliflozin;metformin hydrochloride)
- Region
- 🇪🇺 EU
- Active substance
- ertugliflozin;metformin hydrochloride
- Company
- Merck Sharp & Dohme B.V.
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus, Type 2
- CHMP opinion
- Thu 25 Jan 2018
- EU approval
- Fri 23 Mar 2018
- Application
- EMEA/H/C/004314
- ATC
- A10BD23
- Official record
- www.ema.europa.eu
Indication
Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients not adequately controlled on their maximally tolerated dose of metformin alone in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.
Regulatory milestones
No milestones recorded in the last year.
Follow Segluromet
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.